Search

Your search keyword '"Pérez-Elías, M.J."' showing total 14 results
Start Over Author "Pérez-Elías, M.J."
14 results on '"Pérez-Elías, M.J."'

2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

Author

Brochado Kith, Óscar, Martínez, Isidoro, Berenguer, Juan, Medrano, Luz María, González-García, Juan, Jiménez-Sousa, María Ángeles, Carrero, Ana, Hontañón Antoñana, Víctor, Navarro, Jordi, Guardiola Tey, Jose Maria, Fernández-Rodríguez, Amanda, Resino, Salvador, Miralles, P., López, J.C., Parras, F., Padilla, B., Aldámiz-Echevarría, T, Tejerina, F., Díez, C., Pérez-Latorre, L., Fanciulli, C., Gutiérrez, I., Ramírez, M., Carretero, S., Bellón, J.M., Bermejo, Javier, Arribas, J. R., Montes, M.L., Bernardino, I., Pascual, J.F., Zamora, Francisco, Peña, J.M., Arnalich, F., Díaz, M., Domingo, Pere, Van den Eynde, E., Pérez, M., Ribera, E., Crespo, M., Casado, J.L., Dronda, F., Moreno, A., Pérez-Elías, M.J., Sanfrutos, M.A., Moreno, S., Quereda, C., Arranz, A., Casas, E., de Miguel, J., Schroeder, S., Sanz, J., Santos, I., Bustinduy, M.J., Iribarren, J.A., Rodríguez-Arrondo, F., Von-Wichmann, M.A., Vergas, J., Téllez, M.J., Vinuesa, D., Muñoz, L., Hernández-Quero, J., Ferrer, A., Galindo, M.J., Ortiz, L., Ortega, E., Montero, M., Blanes, M., Cuellar, S., Lacruz, J., Salavert, M., López-Aldeguer, J., Pérez, G., Gaspar, G., Yllescas, M., Crespo, P., Aznar, E., Esteban, H., Instituto de Salud Carlos III, European Regional Development Fund (ERDF/FEDER), Ministerio de Ciencia e Innovación, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Ministerio de Ciencia e Innovación (España), Institut Català de la Salut, [Brochado Ó, Martínez I, Medrano L, Jiménez-Sousa MÁ] Unidad de Infección Viral E Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid, Spain. [Berenguer J] Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. Instituto de Investigación Sanitaria del Gregorio Marañón, Madrid, Spain. [González-García J] Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario 'La Paz', Madrid, Spain. Instituto de Investigacion Sanitaria La Paz (IdiPAZ), Madrid, Spain. [Navarro J] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, lcsh:Medicine, Gene Expression, HIV Infections, Hepacivirus, medicine.disease_cause, 0302 clinical medicine, Interferon, Medicine, Pharmacology (medical), Other subheadings::/therapeutic use [Other subheadings], Interferon therapy, Coinfection, virus diseases, Genetic Phenomena::Gene Expression [PHENOMENA AND PROCESSES], General Medicine, Hepatitis C, Middle Aged, Interferó - Ús terapèutic, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, Hepatitis C virus, Peripheral blood mononuclear cell, Virus, HCV clearance, aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::interferones [COMPUESTOS QUÍMICOS Y DROGAS], 03 medical and health sciences, Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interferons [CHEMICALS AND DRUGS], Immune system, Humans, Molecular Biology, Virus Diseases::Coinfection [DISEASES], Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, virosis::coinfección [ENFERMEDADES], Research, lcsh:R, Biochemistry (medical), HIV, Cell Biology, medicine.disease, Expressió gènica, HIV/HCV coinfection, 030104 developmental biology, Virosis, PBMCs, Immunology, Leukocytes, Mononuclear, Gene expression, Interferons, business, fenómenos genéticos::expresión génica [FENÓMENOS Y PROCESOS]
Abstract

Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón HIV/HCV coinfection; Immune system; Interferon therapy Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR

Published
2021
Full Text
View/download PDF

4. “Real Life” Data on Daas Use among HCV-Patients with Moderate to Severe Chronic Kidney Disease not on Hemodialysis

Author

Moreno, A., primary, Vivancos, M.J., additional, Quereda, C., additional, Pérez-Elías, M.J., additional, de Santiago, A.D., additional, Casado, J.L., additional, Bañón, S., additional, Bárcena, R., additional, García-González, M., additional, Sánchez-Conde, M., additional, del Campo, S., additional, Mateos, M.L., additional, and Moreno, S., additional

Published
2016
Full Text
View/download PDF

5. “Real Life” Safety and Efficacy of IFN/RBV-Free, Full-Dose SOF-Based Therapy in Kidney Transplanted Patients

Author

Moreno, A., primary, Fernandez, A., additional, Vivancos, M.J., additional, Pérez-Elías, M.J., additional, Quereda, C., additional, Elías, S., additional, Liaño, F., additional, García-González, M., additional, Graus, J., additional, del Campo, S., additional, de Santiago, A.D., additional, Mateos, M.L., additional, Bárcena, R., additional, and Moreno, S., additional

Published
2016
Full Text
View/download PDF

6. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007–2012)

Author

Monge, S., primary, Díez, M., additional, Alvarez, M., additional, Guillot, V., additional, Iribarren, J.A., additional, Palacios, R., additional, Delgado, R., additional, Jaén, A., additional, Blanco, J.R., additional, Domingo, P., additional, Portilla, J., additional, Pérez Elías, M.J., additional, and Garcia, F., additional

Published
2015
Full Text
View/download PDF

11. 484 IMPACT OF HIV-COINFECTION ON THE OUTCOME OF VIRAL CIRRHOSIS LIVER TRANSPLANT CANDIDATES AT A REFERENCE CENTER FROM 2001–2008 AND PREDICTORS OF POST-TRANSPLANT SURVIVAL

Author

Moreno, Ana, primary, Bárcena, R., additional, del Campo, S., additional, Muriel, A., additional, Quereda, C., additional, Graus, J., additional, Pérez-Elías, M.J., additional, Fortun, J., additional, Blesa, C., additional, Martinez, A., additional, Arevalillo, M., additional, Moreno, Alberto, additional, Mateos, M.L., additional, and Moreno, S., additional

Published
2009
Full Text
View/download PDF

12. 444 PREVALENCE, RISK FACTORS AND OUTCOME OF FIBROSING CHOLESTATIC HEPATITIS IN VIRAL CIRRHOSIS LIVER TRANSPLANT RECIPIENTS AT A REFERENCE CENTER FROM 2001–2008

Author

Bárcena, R., primary, Moreno, Ana, additional, del Campo, S., additional, Varona, C., additional, Mateos, M.L., additional, Quereda, C., additional, Graus, J., additional, Arocena, C., additional, Pérez-Elías, M.J., additional, Nuño, J., additional, Muriel, A., additional, Fortun, J., additional, Moreno, S., additional, and Moreno, Alberto, additional

Published
2009
Full Text
View/download PDF

14. Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?

Author

Pérez-Elías, M.J., Palter, D. Podzamczer, Bosch, P. Ventayol, Jarrín, I., Castro, A., Rubio-Rodríguez, D., and Rubio-Terrés, C.

Abstract

Aunque el tratamiento antirretroviral (TAR) del VIH/SIDA se introdujo en 1987, la mejora en la progresión de la enfermedad y reducción de la mortalidad poblacional no se observó hasta 1996, con la combinación de tres o más fármacos. El objetivo fue estimar el beneficio clínico y económico del TAR en España en el periodo de 32 años comprendido entre 1987 y 2018.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results